<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03703466</url>
  </required_header>
  <id_info>
    <org_study_id>17041</org_study_id>
    <secondary_id>I3Y-MC-JPCP</secondary_id>
    <secondary_id>2018-001853-28</secondary_id>
    <nct_id>NCT03703466</nct_id>
  </id_info>
  <brief_title>A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer</brief_title>
  <official_title>An Open-Label, Randomized Phase 2 Study of the Impact of Food on Tolerability When Receiving Abemaciclib for Patients With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to examine the side effects that participants with
      metastatic breast cancer experience when taking abemaciclib with or without food.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 28, 2018</start_date>
  <completion_date type="Anticipated">February 20, 2021</completion_date>
  <primary_completion_date type="Actual">July 29, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Severe Diarrhea (≥ Grade 3)</measure>
    <time_frame>Cycle 3 (28 Day Cycles)</time_frame>
    <description>Percentage of participants with severe diarrhea (≥ grade 3)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Prolonged Grade 2 Diarrhea</measure>
    <time_frame>Cycle 3 (28 Day Cycles)</time_frame>
    <description>Percentage of participants with prolonged grade 2 diarrhea</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Dose Reductions Due to Diarrhea</measure>
    <time_frame>Cycle 3 (28 Day Cycles)</time_frame>
    <description>Percentage of participants with dose reductions due to diarrhea</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Dose Interruptions Due to Diarrhea</measure>
    <time_frame>Cycle 3 (28 Day Cycles)</time_frame>
    <description>Percentage of participants with dose interruptions due to diarrhea</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants who Discontinue Treatment due to Diarrhea</measure>
    <time_frame>Cycle 3 (28 Day Cycles)</time_frame>
    <description>Percentage of participants who discontinue treatment due to diarrhea</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Utilizing Antidiarrheals</measure>
    <time_frame>Cycle 3 (28 Day Cycles)</time_frame>
    <description>Percentage of participants utilizing antidiarrheals</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Mean Steady State Exposure of Abemaciclib</measure>
    <time_frame>Postdose Cycle 1 Day 1 through Postdose Cycle 3 Day 1 (28 Day Cycles)</time_frame>
    <description>PK: Mean steady state exposure of abemaciclib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Mean Steady State Exposure of Abemaciclib Metabolite LSN2839567</measure>
    <time_frame>Postdose Cycle 1 Day 1 through Postdose Cycle 3 Day 1 (28 Day Cycles)</time_frame>
    <description>PK: Mean steady state exposure of abemaciclib metabolite LSN2839567</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Mean Steady State Exposure of Abemaciclib Metabolite LSN3106726</measure>
    <time_frame>Postdose Cycle 1 Day 1 through Postdose Cycle 3 Day 1 (28 Day Cycles)</time_frame>
    <description>PK: Mean steady state exposure of abemaciclib metabolite LSN3106726</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Abemaciclib with a Meal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abemaciclib given orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abemaciclib without a Meal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abemaciclib given orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abemaciclib without Regard to Food</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abemaciclib given orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abemaciclib</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Abemaciclib with a Meal</arm_group_label>
    <arm_group_label>Abemaciclib without Regard to Food</arm_group_label>
    <arm_group_label>Abemaciclib without a Meal</arm_group_label>
    <other_name>LY2835219</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis of HR+, HER2− metastatic breast cancer (mBC).

          -  Have all of the following:

               -  Recurrent, locally advanced, unresectable or mBC with disease progression
                  following anti-estrogen therapy.

               -  Prior treatment with chemotherapy for locally advanced or metastatic disease.

               -  No prior treatment with cyclin-dependent kinases (CDK) 4 and 6 inhibitor.

          -  Have Eastern Cooperative Oncology Group performance status (ECOG PS) ≤1.

          -  Have discontinued all previous treatments for cancer and recovered from the acute
             effects of therapy.

          -  Have adequate organ function.

          -  Women of child-bearing potential must have a negative pregnancy test.

          -  Are able to swallow tablets/capsules.

        Exclusion Criteria:

          -  Are currently receiving treatment in a clinical study involving an investigational
             product.

          -  Have a serious concomitant systemic disorder.

          -  Have symptomatic central nervous system (CNS) malignancy or metastasis.

          -  Have a symptomatic Human Immunodeficiency Virus (HIV) infection or symptomatic
             activated/reactivated hepatitis A, B, or C.

          -  Have a personal history of syncope of either unexplained or cardiovascular etiology,
             ventricular tachycardia, ventricular fibrillation, or sudden cardiac arrest.

          -  Have a history of any other cancer.

          -  Had major surgery within 14 days prior to randomization.

          -  Are breastfeeding.

          -  Have received treatment with a drug that has not received regulatory approval for any
             indication within 14 or 21 days of the initial dose of study drug for a
             nonmyelosuppressive or myelosuppressive agent, respectively.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mater Private Hospital</name>
      <address>
        <city>North Sydney</city>
        <state>New South Wales</state>
        <zip>2291</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ashford Cancer Centre Research</name>
      <address>
        <city>Kurralta Park</city>
        <state>South Australia</state>
        <zip>5037</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian Oncological Research Center</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volgograd regional clinical oncology dispensary</name>
      <address>
        <city>Volgograd</city>
        <zip>400138</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Quirón Salud Barcelona-Instituto Oncológico Baselga</name>
      <address>
        <city>Barcelona</city>
        <zip>08023</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ruber Internacional</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akdeniz University Medical Faculty</name>
      <address>
        <city>Antalya</city>
        <zip>07058</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trakya University Faculty of Medicine</name>
      <address>
        <city>Edirne</city>
        <zip>22030</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Park Izmir Hospital</name>
      <address>
        <city>Izmir</city>
        <zip>35575</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inonu University Medical Faculty</name>
      <address>
        <city>Malatya</city>
        <zip>44280</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Turkey</country>
  </location_countries>
  <removed_countries>
    <country>Ukraine</country>
  </removed_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/metastatic-breast-cancer/JPCP</url>
    <description>A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer</description>
  </link>
  <verification_date>September 1, 2019</verification_date>
  <study_first_submitted>October 5, 2018</study_first_submitted>
  <study_first_submitted_qc>October 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2018</study_first_posted>
  <last_update_submitted>September 2, 2019</last_update_submitted>
  <last_update_submitted_qc>September 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <pending_results>
    <submitted>July 17, 2020</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

